www.technavio.comenquiry@technavio.com

Global Ischemic Heart Disease (IHD) Drugs Market

2015-2019

Covered in this Report

• The report covers the present scenario and the growth prospects of the global IHD drugs market for the period 2015-2019.

• To calculate the market size, we consider the revenue generated from the sales of various branded therapies and generics, along with the drugs used as off-label for the treatment of IHD.

• The Technavio report, namely Global IHD Drugs Market 2015-2019, is based on an in-depth market analysis, with inputs from industry experts.

• We covers the Americas, APAC and EMEA markets. We also discuss the key vendors operating in this market.

Global Ischemic Heart Disease (IHD) Drugs Market 2015-2019

USA – CANADA – UK – CHINA – INDIA

Market Overview• IHD is an abnormal condition of the human body marked

by narrowing or blocking of the arteries that supply blood to the heart.

• It results from the buildup of plaque in the arteries.

• The condition often arises during excitement and exertion when heart requires more blood supply.

• This leads to recurrent chest pain and discomfort due to lack of sufficient blood supply, a condition known as angina pectoris.

• Technavio analysts forecast the global IHD drugs market to grow at a CAGR of 3.61% during 2014-2019.

To know more aboutGlobal Ischemic Heart Disease (IHD) Drugs Market 2015-2019,

please mail us atenquiry@technavio.com

USA – CANADA – UK – CHINA – INDIA

Key Vendors and Regions

• AstraZeneca

• Bayer

• Eli Lilly

• Novartis

• Pfizer

• Sanofi

• Actelion

• Amgen

• Baxter

View Our Report: Global Ischemic Heart Disease (IHD) Drugs Market 2015-2019

• Americas

• APAC

• EMEA

Vendors Regions

USA – CANADA – UK – CHINA – INDIA

Key Findings

USA – CANADA – UK – CHINA – INDIA

• The market presents several growth opportunities for the vendors.

• Different vendors in the market are increasingly forming strategic alliances and engaging in mergers and acquisitions to increase their market share.

• The anti-coagulant Xarelto is co-developed by Bayer, and Janssen and Janssen has the exclusive rights to market the drug in the US.

• Similarly, Effient was co-developed by Eli Lilly and Daiichi Sankyo.

• Eli Lilly has exclusive marketing rights in the US and Daiichi Sankyo has exclusive marketing rights of the drug in Japan.

• Such collaborations help in the increased penetration of the drug in a particular market and thereby help in the increased sales.

• This is expected to fuel the growth of the market.

Key Questions Answered in Our Report

• What will the market size be in 2019 and what will the growth rate be?

• What are the key market trends?

• What is driving this market?

• What are the challenges to market growth?

• Who are the key vendors in this market space?

• What are the market opportunities and threats faced by the key vendors?

• What are the strengths and weaknesses of the key vendors?

Have a question of your own about this report?

Ask our Analysts

USA – CANADA – UK – CHINA – INDIA

• Decision makers and influencers in sales & marketing, strategy, product and R&D teams rely on research from Technavio. We have a large and growing base of happy customers worldwide. Our customers include technology suppliers, end users, consulting companies, investment firms and research institutes.

• Technavio was founded in 2003 in London. We have about 300 analysts globally. We cover more than 500 technologies across 80 countries. Traditional media such as Forbes Asia and New York Times, along with other web media portals, like to quote us.

About Technavio

Some of our clients include:ACT Global, Flextronics, Huawei Technologies Co, Infosys, Harris Corporation, Infosys, Intercad, Hidaka Precision Tools & Dies Company, Huawei Technologies Co, American Capital, Analysis Group, Netscout, NTT DoCoMo

USA – CANADA – UK – CHINA – INDIA

View Our Report

Global Ischemic Heart Disease (IHD) Drugs Market 2015-2019

110 Pages | SKU: IRTNTR6611

For media enquiries,

please drop us a mail at

media@technavio.com

For more on the scope of the report, mail us at

enquiry@technavio.com

Thank You!

Mail us at: enquiry@technavio.comYou can visit us at:www.technavio.com

USA – CANADA – UK – CHINA – INDIA